T cell dependence on mTOR signaling

Cell Cycle

Volumn 8, Issue 4, 2009, Pages 545-548

  Mills, Robyn E ^a   Jameson, Julie M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cell proliferation; Cell trafficking; Signaling, skin; T cell

Indexed keywords

CYTOKINE; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

CANCER THERAPY; CELL GROWTH; CELL METABOLISM; CELL STRUCTURE; CELL SURVIVAL; DRUG SENSITIVITY; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; NONHUMAN; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

MAMMALIA;

EID: 61449212998     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.4.7625     Document Type: Review

References (29)

1. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007; 19:162-72.
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84.
3. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127:125-37.
4. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-75.
5. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-45.
6. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8.
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-302.
8. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68.
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101.
10. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008; 17:2934-48.
11. Mills RE, Taylor KR, Podshivalova K, McKay DB, Jameson JM. Defects in skin gammadelta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol 2008; 181:3974-83.
12. + regulatory T cells. Blood 2005; 105:4743-8.
13. + cells. J Exp Med 2008; 205:565-74.
14. + T cells. Blood 2008; 111:453-62.
15. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-47.
16. + regulatory T cells. Blood 2006; 107:1018-23.
17. + dendritic epidermal cells. Cell 1988; 55:837-47.
18. Jameson JM, Cauvi G, Witherden DA, Havran WL. A keratinocyte-responsive gammadelta TCR is necessary for dendritic epidermal T cell activation by damaged keratinocytes and maintenance in the epidermis. J Immunol 2004; 172:3573-9.
19. Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gammadelta antigen receptors. Science 1991; 252:1430-2.
20. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294:605-9.
21. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for skin gammadelta T cells in wound repair. Science 2002; 296:747-9.
22. Jameson JM, Cauvi G, Sharp LL, Witherden DA, Havran WL. Gammadelta T cell-induced hyaluronan production by epithelial cells regulates inflammation. J Exp Med 2005; 201:1269-79.
23. Sharp LL, Jameson JM, Cauvi G, Havran WL. Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. Nat Immunol 2005; 6:73-9.
24. Fox CJ, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005; 201:259-66.
25. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180:5794-8.
26. Hernandez-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernandez-Garcia R, CalderonSalinas JV, Reyes-Cruz G, et al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 2007; 282:23708-15.
27. Murooka TT, Rahbar R, Platanias LC, Fish EN. CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood 2008; 111:4892-901.
28. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 2008; 9:513-21.
29. Stein JV, Nombela-Arrieta C. Chemokine control of lymphocyte trafficking: a general overview. Immunology 2005; 116:1-12.